Bellicum Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch BLCM and buy or sell other stocks, ETFs, and their options commission-free!

About BLCM

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. 

CEO
Dave Maggio
CEODave Maggio
Employees
Employees
Headquarters
Houston, Texas
HeadquartersHouston, Texas
Founded
2004
Founded2004
Employees
Employees

BLCM Key Statistics

Market cap
889.60K
Market cap889.60K
Price-Earnings ratio
-0.06
Price-Earnings ratio-0.06
Dividend yield
Dividend yield
Average volume
27.22K
Average volume27.22K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$1.31
52 Week high$1.31
52 Week low
$0.06
52 Week low$0.06

Stock Snapshot

As of today, Bellicum Pharmaceuticals(BLCM) shares are valued at $0.07. The company's market cap stands at 889.6K, with a P/E ratio of -0.06.

Bellicum Pharmaceuticals(BLCM) stock opened on 2026-03-10 at —. The price climbed to — and dipped to —.

Bellicum Pharmaceuticals(BLCM) shares are trading with a volume of 0, against a daily average of 27.22K.

In the last year, Bellicum Pharmaceuticals(BLCM) shares hit a 52-week high of $1.31 and a 52-week low of $0.06.

In the last year, Bellicum Pharmaceuticals(BLCM) shares hit a 52-week high of $1.31 and a 52-week low of $0.06.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.